SYNVIVO INC.

Company Overview

The company offers the SynVivo platform, a proprietary microfluidic platform, to study drug delivery, drug discovery, and cellular behavior in real time. The company’s chip technology is used to develop personalized medicines for various cancer therapies. The company’s chips can support a microvascular network that simulates the circulation inside any tissue concerning flow, shear, and pressure. The successful coupling of digitized tissue imaging with silicon etching technologies allows SynVivo to design and manufacture microfluidic chips that can be adapted for various uses. All chip designs incorporate ports for introducing cells and reagents and collecting effluent for analysis. The company’s cancer chips are designed using the patient’s tumor cells to mimic the microenvironment of the patient’s tumor. The company has a strong distribution network for its products in the U.S., Europe, and Asia. Besides chip products, the company offers screening services, including target validation, biomarker analysis, compound screening, ADME/Tox, and mechanism of action (MOA) studies.

Company's Business Segments

• 3D Tissue and Organ-on-Chip Models : This segment is a Cell-based Microfluidic Organ-on-Chip Platform that provides a Biologically Realistic Microenvironment for the real-time study of Cellular Behavior, Drug Delivery, Drug Discovery.